Drug Company Reprimanded for False Advertising

Novo Nordisk Pharmaceuticals of Denmark violated federal regulations for inaccurately representing the type 2 drug Prandin (repaglinide) in promotional materials, according to the U.S. Food and Drug Administration (FDA).

In a May 1 statement, the FDA announced that the drug manufacturer understated the risks of Prandin and inflated its efficacy in advertising paraphernalia such as posters, sales aids and professional exhibits.

The FDA asked that Novo Nordisk immediately discontinue those materials and any others making such claims.

In an interview with Reuters Health, Novo Nordisk spokeswoman Susan Jackson denied that the company violated FDA regulations.

Leave a Reply

Your email address will not be published. Required fields are marked *


Time limit is exhausted. Please reload CAPTCHA.